Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED | N.MMED.WA | N.MMED.WR | N.MMED.WS

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Post by digger144on Oct 11, 2012 8:30pm
229 Views
Post# 20475783

This was the Over-hang...

This was the Over-hang...

Back on August 14, 2012 my post did reference to the pressure that Wade Dawe would be under:

Wade Dawe, President & CEO did an excellent job during the Conference Call and furthermore he is doing just as well building the employee roster...Brigus is fully staffed! He isplaying hardball at this point when it comes to raising further capital, he will attempt to get thisbaby higher before making a decision to add additional funds...25 million in the bank is significant...but..they must improve profitability to eliminate Private Placements...the cash burn moving forward will dictate further action. There is no doubt that the "forces that be" are putting the pressure on him by keeping the share price range bound...hitting targets will take care of that game!
Read more at https://www.stockhouse.com/bullboards/messagedetail.aspx?s=BRD&t=LIST&m=31382299&l=0&pd=0&r=0#XEKMBBgJz0IfBGsY.99

The over-hang is now lifted...."they" got what they wanted...."they" win most of the time!

Let's go!

Digger144

P.S. It is all part of the process...the story is on track...Love it!

Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse